Image of Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

LITERATURE

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes


The cardiovascular safety profile of dapagliflozin, a selective inhibitor of sodium–
glucose cotransporter 2 that promotes glucosuria in patients with type 2 diabetes,
is undefined.


Availability

REQJ398-01Titan CenterAvailable

Detail Information

Series Title
-
Call Number
-
Publisher : .,
Collation
-
Language
English
ISBN/ISSN
-
Classification
NONE
Content Type
-
Media Type
-
Carrier Type
-
Edition
-
Subject(s)
Specific Detail Info
N Engl J Med 2019;380:347-57.
Statement of Responsibility

Other version/related

No other version available


File Attachment



Information


RECORD DETAIL


Back To Previous